2 results
Approved WMOWill not start
Primary Objective: - To evaluate the efficacy of PF-06651600 and PF-06700841 at Week 8 in subjects with moderate to severe UC. Secondary Objective(s): - To evaluate the safety and tolerability of PF-06651600 and PF-06700841 in subjects with moderate…
Approved WMOPending
Primary Objective: • To evaluate the ability to concentrate the radiotracer in prostatic cancer lesions ( with respect to accumulation in background tissues) by prostatic artery injection (PAI), especially within the prostate gland compared to…